Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYENNASDAQ:MRNSNASDAQ:OBSVNASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYENEyenovia$15.96+51.1%$3.99$0.85▼$124.80$45.97M2.471.26 million shs4.63 million shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.84 million shs260 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs300 shsRANIRani Therapeutics$0.54+1.2%$0.65$0.46▼$4.19$30.92M-0.02831,297 shs112,613 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYENEyenovia0.00%+46.69%+227.05%+1,616.68%-77.12%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-54.24%OBSVObsEva0.00%0.00%0.00%0.00%0.00%RANIRani Therapeutics0.00%-2.54%-3.93%-51.96%-85.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYENEyenovia2.6195 of 5 stars3.05.00.00.03.00.00.6MRNSMarinus Pharmaceuticals2.3188 of 5 stars3.20.00.04.20.61.70.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ARANIRani Therapeutics1.4911 of 5 stars3.51.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYENEyenovia 2.00Hold$2.00-87.47% DownsideMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideOBSVObsEva 0.00N/AN/AN/ARANIRani Therapeutics 3.00Buy$7.331,263.07% UpsideCurrent Analyst Ratings BreakdownLatest OBSV, RANI, EYEN, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYENEyenovia$60K766.08N/AN/A($695.52) per share-0.02MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ARANIRani Therapeutics$1.03M30.02N/AN/A$0.06 per share8.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYENEyenovia-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ARANIRani Therapeutics-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)Latest OBSV, RANI, EYEN, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYENEyenoviaN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYENEyenoviaN/A0.340.34MRNSMarinus PharmaceuticalsN/A1.661.47OBSVObsEvaN/A0.610.61RANIRani Therapeutics2.750.880.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYENEyenovia25.84%MRNSMarinus Pharmaceuticals98.80%OBSVObsEva17.52%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipEYENEyenovia7.10%MRNSMarinus Pharmaceuticals5.46%OBSVObsEva14.40%RANIRani Therapeutics53.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYENEyenovia402.88 million2.68 millionOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableOBSVObsEva5077.97 million66.74 millionNot OptionableRANIRani Therapeutics11057.48 million26.84 millionOptionableOBSV, RANI, EYEN, and MRNS HeadlinesRecent News About These CompaniesRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13, 2025 | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comRani Therapeutics Reports 2024 Financial Results and UpdatesMarch 31, 2025 | tipranks.comRani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comRani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateMarch 31, 2025 | globenewswire.comAn Overview of Rani Therapeutics Hldgs's EarningsMarch 28, 2025 | benzinga.comStifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)March 27, 2025 | markets.businessinsider.comRani announces pharmacokinetic, pharmacodynamic data from RT-114 trialMarch 27, 2025 | markets.businessinsider.comRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIran Conflict Fuels Fertilizer Stocks’ Bullish SetupBy Gabriel Osorio-Mazilli | June 16, 2025View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeBy Nathan Reiff | June 9, 2025View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeOBSV, RANI, EYEN, and MRNS Company DescriptionsEyenovia NASDAQ:EYEN$15.96 +5.40 (+51.14%) Closing price 07/2/2025Extended Trading$15.96 0.00 (0.00%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Rani Therapeutics NASDAQ:RANI$0.54 +0.01 (+1.17%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.54 0.00 (0.00%) As of 07/3/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
